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Abstract
Background: Antisocial personality disorder (ASPD) is an under-researched mental disorder. Systematic reviews and
policy documents identify ASPD as a priority area for further treatment research because of the scarcity of available
evidence to guide clinicians and policymakers; no intervention has been established as the treatment of choice for
this disorder. Mentalization-based treatment (MBT) is a psychotherapeutic treatment which specifically targets the
ability to recognise and understand the mental states of oneself and others, an ability shown to be compromised
in people with ASPD. The aim of the study discussed in this paper is to investigate whether MBT can be an
effective treatment for alleviating symptoms of ASPD.
Methods: This paper reports on a sub-sample of patients from a randomised controlled trial of individuals recruited for
treatment of suicidality, self-harm, and borderline personality disorder. The study investigates whether outpatients with
comorbid borderline personality disorder and ASPD receiving MBT were more likely to show improvements in symptoms
related to aggression than those offered a structured protocol of similar intensity but excluding MBT components.
Results: The study found benefits from MBT for ASPD-associated behaviours in patients with comorbid BPD and ASPD,
including the reduction of anger, hostility, paranoia, and frequency of self-harm and suicide attempts, as well as the
improvement of negative mood, general psychiatric symptoms, interpersonal problems, and social adjustment.
Conclusions: MBT appears to be a potential treatment of consideration for ASPD in terms of relatively high level of
acceptability and promising treatment effects.
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Background
Borderline personality disorder (BPD) and antisocial per-
sonality disorder (ASPD) are both disorders with high
levels of comorbid psychiatric illness. The most frequent
comorbid psychiatric disorders in BPD are anxiety and
affective disorders, with lifetime prevalence for these at
approximately 85 %, followed by substance use disorders
at approximately 79 % [1–4]. Co-existence of other psy-
chiatric disorders in BPD has been reported as 41–83 %
for major depression, 12–39 % for dysthymia [5], and
39 % for narcissistic personality disorder [6, 7]. Regard-
ing antisocial personality disorder (ASPD), over 90 % of
those with the condition have at least one other psychi-
atric disorder [8], at least 50 % have co-occurring anxiety
disorders [9] and 25 % have a depressive disorder [10].
Notwithstanding the varying current views in relation to
the classification of categories of personality disorder
[11, 12], individuals who meet criteria for both ASPD
and BPD can be considered as showing a particularly
complex and severe form of personality disorder in so
far as they are likely to present with particularly high
levels of both DSM Axis I and Axis II comorbidity [13].
Amongst the general (UK) population, the prevalence of
individuals meeting both BPD and ASPD diagnostic cri-
teria is low (0.3 %) [14], but is increased in forensic sam-
ples with a higher degree of presumed dangerousness; it
has been found to be significantly associated with a
greater degree of violence [15, 16].
There is sufficient overlap between ASPD and BPD
that considering them as separate disorder entities may
seem unwarranted [11]. Yet, while future classifications
may do away with the distinction [17], or at least sub-
stantially modify it (as implied by Section III of DSM-5),
current nosology incorporates the difference notwith-
standing similarities in symptomatology [18] and trait
domains (namely, antagonism and disinhibition) [19]. In
particular, crossover includes marked impulsivity and
unpredictability, difficulties with emotional regulation
and controlling anger, disregard for safety of self, and be-
haviour that can be considered by others to appear ma-
nipulative (for those with BPD, such behaviour is
conducted with the intention of eliciting care and con-
cern from others; for those with ASPD, such behaviour
is conducted with the intention of gaining personal
profit and power over others) [20–22]. Nonetheless, it is
easy to see why the two disorders may be considered as
distinctly different from each other. The key, frequently-
noted differences include the following: those diagnosed
with ASPD tend to have an inflated self-image, whilst
those diagnosed with BPD tend to have a negative and
devalued self-image; those diagnosed with ASPD pose
more of a risk to others due to their tendency towards
interpersonal violence, whilst those diagnosed with BPD
pose more of a risk to themselves due to their tendency
to self-damaging and self-destructive behaviours; those
diagnosed with ASPD tend to lack empathy and be indif-
ferent to or contemptuous of the feelings and sufferings
of others, whilst those diagnosed with BPD are likely to
display reduced cognitive empathy but enhanced
affective empathy (the so-called “borderline empathy
paradox”) [23]. In reality, although the prototypic pre-
sentations of the two diagnoses appear to be at variance
and may be almost polar opposites, the prominent
symptoms appear across diagnostic groups as well as
varying across time—both within and between individ-
uals. A recent study of nearly 1,000 inpatients found a
general personality disorder factor that underlies all per-
sonality disorder diagnoses [18]. Bi-factor analyses of the
DSM personality disorder criteria indicated that they
load on to a general factor that includes all the BPD
criteria, rather than the latter representing a separate
personality disorder category. It appears that BPD
might be better understood as being at the core of
personality pathology more generally, rather than as a
type of personality disorder. This approach helps to
make sense of the high levels of comorbidity with
other personality disorders, including ASPD, found in
BPD patients.
In line with this assumption, we suggest that there may be
a common element of failures in social cognition associated
with both personality disorders [24]; in particular they share
deficits and distortions of mentalization (the process of mak-
ing sense of the self and of others in terms of mental state-
s—e.g. beliefs, thoughts, feelings, desires). It appears that
those with BPD tend to mentalize ‘normally’ except in the
context of attachment relationships, in which emotional
arousal occludes the ability to accurately interpret mind
states (both their own minds and those of others)—particu-
larly when the fear of real or imagined abandonment arises.
Difficulties with mentalization manifest slightly differently
for antisocial individuals, who show a more general and dee-
per impairment, including deficits in the recognition of basic
emotions [25], and perform far worse than controls on sub-
tle tests of mentalizing [26, 27]. Deficits in social cognition
in general and the capacity to link mental states to behav-
iour in particular are commonly identified in association
with antisocial behaviour [28, 29]. Some (but not all [30])
individuals with ASPD show a blend of perspective-taking
problems and difficulty in reading others’ mental states [31–
37]; this is consistent with the mentalization literature’s def-
icit theory as well as other theories of antisocial behaviour
[38, 39]. It has been suggested that one pathway to adult
antisocial personality leads from early child conduct disorder
via alcohol abuse in early adolescence to compromised func-
tion (and maturational delay) of the cognitive control sys-
tem, of which mentalization is a part [40, 41], and which
matures throughout adolescence and into early adulthood.
Hence, deficits in the ability to mentalize could reflect
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compromised (i.e. delayed) development of the cognitive
control system, brought about by early substance misuse.
Mentalization-Based Treatment—a manualised psy-
chotherapeutic intervention which specifically focuses
on improving the capacity to mentalize—has been
shown to be effective for improving clinically significant
and self-reported outcomes for patients with BPD, in-
cluding reducing frequency of suicide, severe self-harm,
and hospital admission as well as improving general
symptomatology and social and interpersonal function-
ing [42]. While the presence of comorbid Axis II diagno-
ses appears to have a negative impact on outcomes for
BPD patients undergoing standard clinical management,
there has been preliminary work to suggest that MBT
may be more beneficial for patients whose BPD is em-
bedded in other Axis II personality disturbances, includ-
ing that of ASPD [43]. The authors propose that the
mentalization model can also be applied to ASPD and
that MBT may be effective for addressing symptoms of
ASPD as well as of BPD.
The mentalization model of antisocial behaviour is de-
velopmental, premised on the dysfunction of the attach-
ment system that then temporarily inhibits affect
regulation and mentalizing abilities [44–47]. Antisocial
behaviour and violence tend to occur when an under-
standing of others’ mental states is developmentally
compromised (fragile) and prone to being lost when the
attachment system is activated by perceived threats to
self-esteem, such as interpersonal rejection or disrespect
[48]. Normally, mentalizing (i.e. envisioning the subject-
ive state of the victim) precludes violence [49]; this
means that individuals with vulnerable mentalizing
capacities can be behaviourally volatile in moments of
interpersonal stress. Supporting the capacity to identify
others’ emotions and intentions may not only assist
social functioning but also reduce the risk of antisocial
behaviour. Indeed, mentalizing has been shown to be a
protective factor against aggression in people with vio-
lent traits [32], encouraging mentalizing has also been
shown to reduce school violence [50, 51], and studies of
forensic patients with personality disorder have found
that participants’ views of the processes by which thera-
peutic change occurred identified realisations that
reflected improved mentalizing [52, 53].
This study tests the hypothesis that patients with co-
morbid BPD and ASPD receiving outpatient MBT would
be more likely to show improvements in symptoms
related to aggression than those offered an outpatient
structured protocol of similar intensity but excluding
MBT components. This comorbid population was se-
lected for pragmatic reasons, as a subsample of a trial
originally designed to compare MBT to Structured
Clinical Management (SCM) in a sample of consecutive
referrals to a personality disorder unit that specialises in
BPD [49]. At the time of the original trial, MBT had not
yet been indicated for ASPD and the trial was not de-
signed with this diagnosis in mind. Nevertheless, our
original design allows us to measure change in import-
ant psychological features directly related to characteris-
tics of ASPD such as anger, hostility, impulsivity (as
reflected in self-harm and suicide) and difficulty in relax-
ing interpersonal control related to loss of dignity, self-
worth and self-respect [54]. Mood disorders, particularly
anxiety and depression, are known to co-occur with ASPD
[9, 55, 56] and to be frequent triggers for aggression [57,
58]. The trial design also enabled us to test whether MBT
may be effective in reducing negative affect states, particu-
larly depression and anxiety. Finally, the study design en-
abled us to measure change due to treatment in common
consequences of aggression, such as psychiatric symptoms
including quality of familial and social relationships, and
subjective wellbeing.
Method
Design
This subgroup analysis was part of a larger pragmatic
randomised superiority trial that investigated MBT as
a treatment for patients with BPD in an outpatient
context by non-specialist mental health practitioners
at a publicly funded clinical service [42]. To control
for the non-specific benefits of a structured treat-
ment, the comparison group also received a protocol-
driven therapy, SCM, in an outpatient context repre-
senting best current clinical practice [59]. Practi-
tioners in both arms received the same level of
training and equivalent supervision.
Participants
Participants were recruited from consecutive referrals
for personality disorder treatment from clinical
services between January 2003 and February 2006. All
participants were assessed using the Structured
Clinical Interview for DSM-IV (SCID-I and SCID-II)
[60, 61]. Inclusion criteria were (1) diagnosis of ASPD
and comorbid BPD; (2) suicide attempt or episode of
life-threatening self-harm within the past 6 months;
and (3) age 18–65. Exclusion criteria were kept to
a minimum. Patients were excluded if they currently
(1) were in long-term psychotherapeutic treatment;
(2) met DSM-IV criteria for psychotic disorder or bi-
polar I disorder; (3) had opiate dependence requiring
specialist treatment; or (4) had mental impairment or
evidence of organic brain disorder. Current psychi-
atric inpatient treatment, temporary residence, drug/
alcohol misuse and comorbid personality disorder
were not exclusion criteria.
One hundred and fifty-eight patients attended for
interview. Of these, five did not have BPD, 94 did not
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have ASPD, two had opiate dependence, one had bipolar
I disorder, one had a psychotic disorder, and three could
not be contacted after the diagnostic interview. Of the
52 patients enrolled, 12 refused randomisation, leaving
40 with a dual diagnosis of ASPD and BPD, who were
randomised to one of the two outpatient treatment pro-
grammes (MBT = 21, SCM = 19). Seventy-five percent of
the MBT group were male, with a mean age of 31.50
(SD = 8.20) years; 8 % were employed and 76 % were re-
ceiving welfare benefits at the time. They had a mean
number of 3.1 (SD = 1.3) Axis I and 3.3 (SD = 0.9) Axis II
diagnoses. Of the SCM group, 62 % were males, with a
mean age of 30.00 (SD = 7.10) years; 6 % were employed
and 94 % were receiving benefits. They had a mean
number of 3.0 (SD = 1.5) Axis I and 2.9 (SD = 1.0) Axis II
diagnoses. None of the participants had ever been mar-
ried1. We tested the relative severity of the groups in
terms of the number of Axis I and II diagnoses and
found no differences on the Kruskal-Wallis test on either
of these variables (χ 2 = 0.05, df = 1, p = .84, and χ 2 =
0.66, df = 1, p = .41 for number of Axis I and Axis II
diagnoses respectively).
Procedure
Patients referred to St Ann’s Hospital’s specialist person-
ality disorder service were randomly assigned to one of
two active treatment arms and assessed at entry and
over the course of an 18-month treatment at 6, 12, and
18 months. The study was approved by Barnet, Enfield
and Haringey Local Research and Ethics Committee (ref:
658) and conducted at the Halliwick personality disorder
service and in a community outpatient facility. Patients
were provided with written information and consented
only after complete description of the study. Randomisa-
tion followed consent, enrolment, and baseline assess-
ment by a research assistant at St Ann’s Hospital.
Treatment allocation was made offsite via telephone
randomisation using a stochastic minimisation pro-
gram (MINIM) balancing for age (blocked as 18–25,
26–30, >30 years), gender, and presence of ASPD. A
study psychiatrist informed patients of their alloca-
tion. All treatments were funded by the NHS. Partici-
pants were not paid.
Both treatments were conducted within a structured
framework following principles outlined elsewhere [62]
and summarised in NICE guidance for BPD [21]. This in-
cluded crisis contact and crisis plans, pharmacotherapy,
general psychiatric review, and written information about
treatment. Crisis plans were developed collaboratively
within each treatment team for all patients. MBT thera-
pists focused on helping patients reinstate mentalizing
during a crisis via telephone contact. SCM therapists fo-
cused on support and problem solving. Efforts were made
to keep all patients in treatment if they missed
appointments. Both therapies were offered weekly to en-
sure equivalent therapeutic intensity in both groups. All
patients were offered approximately 140 sessions of ther-
apy in total. Seventy-five percent across the two groups
met criteria for completers - at least 70 sessions attended
over the first year. There was no difference in the distribu-
tion of completer categories across the groups (χ 2 = 1.87,
df = 2, p = .18). We also tested the amount of treatment
received by each group in terms of individual, group and
total sessions and there were no differences on the
Kruskall-Wallis test on any of these variables (χ 2 = 0.86,
df = 1, p = .38, χ 2 = 1.51, df = 1, p = .22, χ 2 = 1.80, df = 1,
p = .17 for individual, group and total sessions
respectively).
Mentalization-based treatment MBT is a manualised,
structured treatment that integrates cognitive, psycho-
dynamic and relational components of therapy, with a
basis in attachment theory and a rigorous focus on
improving mentalizing (the ability to understand the
mental states of oneself and others). It consisted of
18 months of weekly combined individual and group
psychotherapy provided by two different therapists [63].
Structured clinical management An outpatient SCM
protocol was developed through the Barnet, Enfield and
Haringey Mental Health NHS Trust to reflect best gen-
eric practice for personality disorder offered by non-
specialist practitioners within UK psychiatric services.
Weekly individual and group sessions were offered, with
appointments every 3 months for psychiatric review.
Therapy was based on a counselling model closest to a
supportive approach with case management, advocacy
support, and problem-oriented psychotherapeutic inter-
ventions; the treatment model has been manualised [59].
Medication Patients were prescribed medication by a
member of the treatment team (MBT condition) or their
consultant psychiatrist (SCM condition). All patients
were offered medication reviews every 3 months. All
prescribers were asked to adhere to APA guidelines [64].
Prescribing patterns and dosage were monitored by re-
view of medical records every 6 months.
Outcomes
Outcomes were classified according to their relation to
aggression. Anger, domineering relationships, hostility,
paranoid ideation and signs of impulsivity (suicidality
and self-harm) were the target outcomes as indicators of
problematic aggression. Anxiety, depression, and a sum-
mary indicator of psychiatric symptomatic distress were
assessed as possible drivers of overt aggression. Lastly,
we addressed consequences secondary to problematic
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aggression: problems in interpersonal relationships, so-
cial, familial and global functioning.
Measures
Clinician-rated anger was assessed at the beginning
and end of treatment by assessors blind to treatment
group using SCID-II questions related to item 4 (‘ir-
ritability and aggressiveness as indicated by repeated
physical fights and assaults’) of the diagnostic criteria
for ASPD. Patients’ subjective experience of hostility,
paranoid ideation and general symptom distress was
measured using the Symptom Checklist-90—Revised
(SCL-90-R) [65], and depression was assessed by
using the Beck Depression Inventory (BDI) [66]. The
hostility subscale of the SCL-90 consists of 6 items
(items 11, 24, 63, 67, 74, 81) measuring feelings of
annoyance and irritability and urges to hurt others as
well as actions such as breaking things, getting into
arguments, and shouting at others or throwing things.
The paranoid ideation subscale is also 6 items, identi-
fying feelings that others are to blame and unappre-
ciative along with a general sense of distrust in others
and the world. Self-harm and suicidality were assessed
at interview and confirmed from medical records.
Social adjustment and interpersonal functioning were
measured using the modified Social Adjustment Scale
(SAS)–self-report [67], and the Inventory of Interpersonal
Problems (IIP)–circumplex version [68, 69], which pro-
vided a scale of domineering as well as general interper-
sonal problems. The instruments provide an assessment
of an individual’s work, spare time activities, and family
life, as well as difficulties with interpersonal functioning.
Hospital admission statistics were based on local compu-
terised medical records. Global functioning was rated at
the beginning and end of treatment using the Global As-
sessment of Functioning (GAF), which has been found to
show less improvement than diagnostic symptoms in
studies of a naturalistic follow-on design [70]. Assessors
were blind to treatment group, and their assessment was
compared with clinician ratings to indicate reliability.
Analysis plan
Treatment group differences were assessed with t tests
for independent samples. Change in continuous vari-
ables was analysed with mixed effects linear regressions
as function of group treatment and time. Incidence of
suicidal and severe self-injurious behaviours and epi-
sodes of hospitalisation, assessed in 6-month periods
both in terms of counts and as dichotomous data
(present or absent in each period), was used to indicate
the severity of life-threatening parasuicidal behaviour
taken at baseline for the 6 months prior to treatment
and for each 6-month period until the end of treatment
at 18 months. Count data were analysed using a mixed
effects Poisson regression model; for binary data a mixed
effects logistic regression model was used.
Results
Target symptoms
Table 1 shows means and standard deviations of anger,
domineering interpersonal style as measured by the IIP,
and hostility as assessed on the SCL-90 at all time points.
Anger, measured by the presence of anger-related criteria
on the SCID-II ASPD module, was collected at baseline
and at the end of the 18 months of treatment. Both the
MBT and SCM groups presented with similar levels of
anger at the beginning of treatment, but differed signifi-
cantly by 18 months (t = 2.05, p < 0.05). Mixed effects re-
gression revealed significant difference in the linear
change observed. Neither the SCM nor the MBT group
showed significant changes in domineering interpersonal
style as measured by the IIP. Self-rated hostility, however,
decreased in both groups. While linear decline was not
statistically significantly steeper, both observed and
model-predicted hostility was significantly lower in the
MBT than the SCM group. Paranoia symptoms, measured
by the SCL-90, and paranoid ideation, measured by the
SCID-II, showed significantly more improvement in the
MBT than the SCM group, and at 18 months, paranoia
and paranoid ideation scores were significantly lower.
Occurrence of suicide attempts, episodes of self-harm
and hospital admissions during the last 6 months were
registered and counted, and summary scores are displayed
in Table 2. A composite variable was created to count the
number of patients free of any of these three severe clin-
ical events in the last 6 months. Mixed effects logistic re-
gression with random intercept confirm the significant
observed end of treatment group differences (62 % vs
21 %). Although the number of patients attempting sui-
cide was not significantly different in the logistic regres-
sion model, the number of suicide attempts modelled
using mixed effects Poisson regression suggested signifi-
cant superiority of MBT over SCM. For self-harm, both
the mean number of self-harm attempts and the number
of those who self-harmed suggested greater benefit for
participants in the MBT group. Similarly, numbers of hos-
pital admissions were lower in this group. At 18 months,
both model-estimated (intention-to-treat) and observed
(per protocol) self-harm frequency were significantly
lower for the MBT group. Model-estimated (mixed-effects
Poisson) frequency of hospital admissions was slightly
lower for the MBT group at 18 months.
Drivers of aggression
Anxiety and depression, as measured by the SCL-90 and
the BDI, were both seen to improve significantly across
both groups during treatment, following a linear pattern
for depression, and both a linear and a quadratic pattern
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for anxiety, suggesting a fast reduction in anxiety during
the first months of treatment. Table 3 shows the
observed means for these two scores ordered by
treatment group and follow-up time point. At the
18-month point, both anxiety and depression scores
(observed and predicted by mixed-effects models)
were significantly lower for the MBT group than
for the SCM group. The combined symptom distress
scores (Global Severity Index; GSI) similarly
suggested greater ultimate benefit from MBT,
although the mixed effects regression did not indi-
cate significantly more rapid (steeper linear change)
improvement.
Secondary consequences of aggression
As indicated in Table 4, patients showed comparable
total scores on the GAF, IIP and SAS measures at
baseline. Mixed-effect models showed a significantly
greater linear improvement with time on GAF, and
greater linear reduction on IIP and SAS adjustment
problems for the MBT group, although both groups
improved substantially. However, patients who
received MBT showed significantly more improve-
ments on overall functioning, interpersonal prob-
lems, and social adjustment scores at the end of
treatment, in comparison to patients who received
SCM.
Table 1 Changes in anger (SCID-II), domineering interpersonal problems (IIP), Hostility (SCL-90) and paranoia (DSM and SCL-90)
Anger (DSM) Domineering (IIP) Hostility (SCL-90)
Unadjusted observed mean (SD) Unadjusted observed mean (SD) Unadjusted observed mean (SD)
MBT SCM t MBT (n = 21) SCM (n = 19) t MBT (n = 21) SCM (n = 19) t
Baseline 2.76 (n = 21) (0.62) 2.68 (n = 19) (0.75) -0.36 -0.12 (0.77) -0.33 (0.40) -0.10 1.73 (1.20) 2.04 (1.04) 0.88
6 months -0.16 (0.73) -0.16 (0.45) -0.02 1.67 (1.08) 1.86 (0.87) 0.61
12 months -0.18 (0.69) -0.23 (0.41) -0.30 1.43 (0.96) 1.88 (0.78) 1.60
18 months 1.25 (n = 8) (0.46) 2.00 (n = 8) (0.93) 2.05* -0.22 (0.43) -0.06 (0.46) 1.06 0.85 (0.60) 1.57 (0.69) 3.53***
Adjusted model coefficients (95 % CI)a Adjusted model coefficients (95 % CI)b Adjusted model coefficients (95 % CI)b
Model: Wald χ2 35.56*** (df = 3)a 3.51 (df = 4) 54.83*** (df = 5)
Linear change
(both groups)
-0.23* (-0.41, -0.04) 0.07 (-0.10, 0.24) -0.48** (-0.84, -0.12)
Quadratic change
(both groups)
0.00 (-0.05, 0.05) -0.17* (-0.32, -0.02)
Differential linear
change (MBT)
-0.28* (-0.54, -0.02)) -0.11 (-0.22, 0.05) -0.27 (-0.54, 0.01)
Group differences
at 18 months
-0.75* (-1.41, -0.09) -0.13 (-0.41, 0.16) -0.60** (-1.02, -0.18)
Paranoia (SCL-90) Paranoid ideation (DSM)
Unadjusted observed mean (SD) Unadjusted observed mean (SD)
MBT (n = 21) SCM (n = 19) t MBT SCM t
Baseline 1.86 (1.03) 1.94 (0.72) 0.29 2.14 (n = 21) (0.91) 2.05 (n = 19) (0.97) -0.30
6 months 1.62 (0.99) 2.00 (0.80) 1.24
12 months 1.52 (1.00) 1.81 (0.78) 1.02
18 months 0.85 (0.57) 1.47 (0.70) 3.06** 1.00 (n = 8) (0.00) 1.88 (n = 8) (0.99) 2.50**
Adjusted model coefficients (95 % CI)c Adjusted model coefficients (95 % CI)d
Model: Wald χ2 22.77*** (df = 3) 22.77*** (df = 3)
Linear change
(both groups)
-0.12 (-0.29, -0.05) -0.12 (-.029, 0.05)
Differential linear
change (MBT)
-0.29* (-0.53, -0.36) -0.28* (-0.53, –0.04)
Group differences at
18 months
-0.75* (-1.51, -0.01) -0.75* (-1.51, 0.01)
MBT Mentalization-Based Treatment, SCM Structured Clinical Management, t t-test for independent samples, χ2 chi-squared, CI confidence interval, df degrees
of freedom
*p < 0.05; **p < 0.01; ***p < 0.001
afixed-effects linear regression
bmixed-effects linear regression with random intercept
cmixed-effects linear regression with random intercept
dmixed-effects linear regression with random slope
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Discussion
The aim of the study was to provide preliminary data to in-
dicate whether MBTcould reduce symptoms related to anti-
social behaviour in patients with comorbid BPD and ASPD
when compared with those offered an outpatient structured
protocol of similar intensity, but excluding mentalizing com-
ponents. The data collected is rare in its inclusivity of indi-
viduals with comorbid personality disorders, a key clinical
group typically excluded from randomised controlled trials,
and the results strongly suggest that MBT is an effective
treatment for patients with BPD and comorbid ASPD.
Patients treated with MBT showed a significantly greater re-
duction in the target symptoms of anger, hostility and
paranoia than those in the SCM group. At the end of treat-
ment, fewer patients in the MBT group presented with im-
pulse control-related problems (suicidality and self-harm),
and the frequency of suicide attempts and self-harm epi-
sodes was also significantly lower. Measures of negative
mood and general psychiatric symptoms, which may identify
a vulnerability to the aggressive acts that are a hallmark of
ASPD, also showed significantly greater improvements and
indicated better adjustment in the MBT group. Similarly,
common sequelae of aggression—poor general functioning,
interpersonal problems and social adjustment at the end of
treatment—were improved following MBT in comparison
with those who received SCM.
Table 2 Changes in impulsive acts (suicidality and self-harm)
Patients without severe clinical events Patients who presented suicide
attempts
Number of suicide attempts
n/N(%) n/N(%) Unadjusted observed mean (SD)
MBT SCM χ2 MBT SCM χ2 MBT (n = 21) SCM (n = 19) t
Baseline 0/21 0.00 % 0/19 0.00 % 19/21 90.48 % 15/19 78.95 % 1.04 1.38 (1.07) 1.32 (0.95) -0.20
6 months 2/21 9.52 % 1/19 5.26 % 0.26 11/21 52.38 % 11/19 57.89 % 0.12 0.57 (0.60) 0.89 (0.99) 1.26
12 months 6/21 28.57 % 2/19 10.53 % 2.03 8/21 38.10 % 10/19 52.63 % 0.85 0.43 (0.60) 0.79 (1.03) 1.37
18 months 13/21 61.90 % 4/19 21.05 % 6.81** 0/21 0.00 % 4/19 21.05 % 4.91* 0.00 (0.00) 0.37 (0.83) 2.04*
Modelled odds ratios (95 % CI) a Modelled odd ratios (95 % CI) a Adjusted model coefficients (95 % CI)b
Model: Wald χ2 12.48** (df = 3) 23.67*** (df = 3) 36.29***
Linear change
(both groups)
8.42* (1.18, 60.15) 0.20** (0.08, 0.51) 0.70** (0.55, 0.88)
Differential linear change
(MBT)
2.83 (0.32, 24.79) 0.34 (0.10, 1.16) 0.61* (0.41, 0.91)
Group differences at
18 months
61.45* (1.17, 60.15) 0.09 (0.01, 1.35) 0.25** (0.09, 0.71)
Patients who self-harmed Number of self-harm episodes Number of hospital admissions
n/N(%) Unadjusted observed mean (SD) Unadjusted observed means (SD)
MBT SCM χ2 MBT (n = 21) SCM (n = 19) t MBT (n = 21) SCM (n = 19) t
Baseline 16/21 76.19 % 14/19 73.68 % 0.03 5.90 (6.69) 3.79 (3.61) -1.23 0.57 (0.60) 0.32 (0.58) -1.37
6 months 17/21 80.95 % 17/19 89.47 % 0.57 3.14 (3.02) 3.11 (3.57) -0.04 0.24 (0.44) 0.21 (0.42) -0.20
12 months 10/21 47.62 % 15/19 78.95 % 4.18* 2.14 (2.87) 2.42 (2.39) 0.37 0.10 (0.30) 0.32 (0.75) 1.24
18 months 8/21 38.10 % 13/19 68.42 % 3.68 0.62 (0.97) 2.63 (3.65) 2.43* 0.00 (0.00) 0.16 (0.37) 1.93*
Modelled odds ratios (95 % CI)a Adjusted model coefficients (95 % CI)b Adjusted model coefficients (95 % CI) b
Model: Wald χ2 13.34** (df = 3) 98.73*** (df = 4) 17.38** (df = 4)
Linear change (both
groups)
0.72 (0.35, 1.49) -0.12 (-0.27, 0.35) 0.89 (0.46, 1.74)
Differential linear change
(MBT)
0.30* (0.10, 0.91) -0.29** (-0.50, -0.08) 0.28 (0.06, 1.27)
Group differences at
18 months
0.03* (0.01, 0.63) -0.66*** (-0.98, -0.34) 0.06* (0.00, 0.81)
MBT Mentalization-Based Treatment, SCM Structured Clinical Management, t t-test for independent samples, χ2 chi-squared, CI confidence interval; df, degrees
of freedom
*p < 0.05; **p < 0.01; ***p < 0.001
amixed-effects logistic regression with random intercept
bmixed-effects Poisson regression with random intercept
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This study has a number of major limitations. A longer-
term follow-up is required to ascertain whether differen-
tial effects are maintained; although a 5-year follow-up
study is underway, as yet we have no data to report. The
study is not adequately powered to demonstrate real dif-
ferences between the two groups and we recognise that
implications of the findings are restricted to the
demonstration of feasibility rather than a demonstration
of effectiveness [71]. The lack of specific outcome mea-
sures for indications of mentalizing ability (e.g. Reading
the Mind in the Eyes Test, Movie for the Assessment of
Social Cognition, Perspectives Taking Test, Reflective
Functioning Questionnaire, Reflective Functioning Scale
on the Adult Attachment Interview) is a major limitation
Table 3 Changes in mood (anxiety and depression) and general symptom distress (GSI)
Anxiety (SCL-90) Depression (BDI) GSI (SCL-90)
Unadjusted observed mean (SD) Unadjusted observed mean (SD) Unadjusted observed mean (SD)
MBT (n = 21) SCM (n = 19) t MBT (n = 21) SCM (n = 19) t MBT (n = 21) SCM (n = 19) t
Baseline 1.83 (0.91) 2.18 (0.82) 1.30 27.51 (11.42) 30.58 (7.51) 0.99 1.75 (0.74) 2.01 (0.55) 1.25
6 months 1.83 (0.85) 2.28 (0.89) 1.62 24.68 (10.45) 29.00 (8.06) 1.45 1.73 (0.80) 2.03 (0.67) 1.29
12 months 1.59 (1.02) 2.05 (0.80) 1.61 19.19 (11.18) 26.56 (8.71) 2.31** 1.52 (0.87) 2.00 (0.66) 1.91*
18 months 1.00 (0.67) 1.62 (0.75) 2.74** 13.14 (7.25) 21.99 (9.20) 3.39*** 0.96 (0.52) 1.57 (0.63) 3.37***
Adjusted model coefficients (95 % CI)a Adjusted model coefficients (95 % CI) Adjusted model coefficients (95 % CI)
Model: Wald χ2 54.07*** (df = 4) 92.30*** (df = 3)a 87.16*** (df = 5)b
Linear change (both groups) -0.61*** (-0.86, -0.36) -2.82*** (-4.05, -1.59) -.060*** (-0.90, -0.29)
Quadratic change (both
groups)
-0.14*** (-0.21, -0.07) -0.18** (-0.32, -0.05)
Differential linear change
(MBT)
-0.08 (-0.24, -0.08) -2.04* (-4.74, -0.34) -0.15 (-0.34, 0.04)
Group differences at
18 months
-0.59* (-1.07, -0.12) -8.96*** (-14.27, -3.65) -0.47** (-0.79, -0.15)
MBT Mentalization-Based Treatment, SCM Structured Clinical Management, t t-test for independent samples, χ2 chi-squared, CI confidence interval, df degrees
of freedom
*p < 0.05; **p < 0.01; ***p < 0.001
amixed-effects linear regression with random intercept
bmixed-effects linear regression with random slope
Table 4 Changes in global functioning (GAF), problems in interpersonal relationships (IIP) and social adjustment (SAS)
GAF (DSM) IIP total SAS total
Unadjusted observed mean (SD) Unadjusted observed mean (SD) Unadjusted observed mean (SD)
MBT SCM t MBT (n = 21) SCM (n = 19) t MBT (n = 21) SCM (n = 19) t
Baseline 38.57 (n = 21) (9.09) 39.74 (n = 19) (8.38) 0.42 2.04 (0.62) 2.11 (0.41) 0.43 2.71 (0.41) 2.81 (0.41) 0.78
6 months 1.87 (0.58) 2.03 (0.40) 1.04 2.53 (0.62) 2.72 (0.49) 1.06
12 months 1.66 (0.51) 2.01 (0.56) 2.06* 2.05 (0.41) 2.63 (0.44) 4.31***
18 months 62.71 (n = 21) (16.66) 51.39 (n = 18) (12.06) -2.39** 1.33 (0.48) 1.76 (0.44) 2.94** 1.69 (0.45) 2.27 (0.51) 3.78***
Adjusted model coefficients (95 % CI) Adjusted model coefficients (95 % CI) Adjusted model coefficients (95 % CI)
Model: Wald χ2 107.57 (df = 3)b 57.47*** (df = 3)b 82.53*** (df = 4)a
Linear change
(both groups)
3.82*** (2.01, 5.63) -0.11** (-0.18, -0.04) -0.22*** (-0.35, -0.10)
Quadratic change
(both groups)
Differential linear
change (MBT)
4.22** (1.75, 6.70) -0.13* (-0.23, -0.03) -0.19* (-0.36 -0.02)
Group differences
at 18 months
11.51** (4.13, 18.89) -0.44** (-0.73, -0.16) -0.60*** (-0.88, -0.33)
MBT Mentalization-Based Treatment, SCM Structured Clinical Management, t t-test for independent samples, χ2 chi-squared, CI confidence interval, df: degrees
of freedom
*p < 0.05; **p < 0.01; ***p < 0.001
amixed-effects linear regression with random slope
bmixed-effects linear regression with random intercept
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that prevents us from gathering information on MBT’s
purported mechanism of change. Additionally, indicators
are required that are more central in the planning of ser-
vices for ASPD than self-reported psychiatric symptoms
and mental health diagnostic status after 18 months, in-
cluding a measure of whether patients continue to meet
criteria for formal diagnosis of ASPD. Furthermore, as this
comorbid population was selected from a personality dis-
order unit that specialises in BPD for pragmatic reasons of
availability, this study is significantly underpowered and
unrepresentative of both the wider ASPD population and
the settings in which they most commonly present.
Nevertheless, the results from this study demonstrate
that randomisation and effective data collection are pos-
sible in a community setting from outpatients with ASPD.
Further, we established that patients by and large adhere
to the treatment protocol (dropout rates of 27 % for MBT
and 26 % for SCM); additionally, qualitatively collected
data (reported fully elsewhere [72]) strongly suggest that
this patient group (perhaps surprisingly) value the inter-
vention, and are particularly appreciative of the group for-
mat. MBT therefore appears to be a potential treatment of
consideration for ASPD in terms of relatively high level of
acceptability and promising treatment effects.
Conclusions
In patients with comorbid ASPD and BPD, MBT is able to
reduce anger, hostility, paranoia, and frequency of self-
harm and suicide attempts, as well as improve negative
mood, general psychiatric symptoms, interpersonal prob-
lems, and social adjustment. The authors recommend that
MBT be further investigated in a significantly powered
sample size of patients with a primary diagnosis of ASPD
to establish its long-term effects on symptomatology
specific to ASPD (e.g. aggression, violence, offending
behaviour) as well as outcomes relevant to other Axis I
and Axis II disorders (e.g. impulsiveness, social function-
ing, general wellbeing), whether MBT has an effect on
diagnostic continuity for ASPD, and whether any changes
can be attributed to change in mentalizing capacity.
Endnotes
1For further demographic and clinical details of the
sample please contact the corresponding author.
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